Literature DB >> 3998061

Genetic transmission of tumoral calcinosis: autosomal dominant with variable clinical expressivity.

K W Lyles, E J Burkes, G J Ellis, K J Lucas, E A Dolan, M K Drezner.   

Abstract

Tumoral calcinosis is a rare inherited metabolic disorder characterized by hyperphosphatemia, elevated serum 1,25-dihydroxyvitamin D levels and periarticular cystic and solid calcifications. Based on previous investigations, the inheritance of this disorder has been postulated to be autosomal recessive. This interpretation was based on finding clinically affected subjects in only single generations of kindreds. We investigated four generations of an affected kindred and found nine subjects with the disease. A unique dental lesion which is specific for this disorder and serves as a phenotypic marker was identified in two generations of the kindred. In all affected subjects, elevated serum 1,25-dihydroxyvitamin D levels were found, although each member did not have the classical clinical findings of tumoral calcinosis. The possibility that this disorder may be variably expressed and have multiple formes frustes has not been previously considered. Using the unique dental lesion as well as the classical clinical and biochemical abnormalities, we found that in this kindred, tumoral calcinosis is transmitted in an autosomal dominant mode, with variable clinical expressivity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3998061     DOI: 10.1210/jcem-60-6-1093

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  A report of familial hyperphosphataemia in an Irish family.

Authors:  S W Li Voon Chong; S Ah Kion; M J Cullen
Journal:  Ir J Med Sci       Date:  1999 Oct-Dec       Impact factor: 1.568

2.  [Teutschländer disease. A rare benign differential diagnosis of proliferative space-occupying lesions in the periarticular soft tissue].

Authors:  T Mumme; H Griefingholt; B Schmidt-Rohlfing; R Müller-Rath; A Kochs
Journal:  Orthopade       Date:  2004-07       Impact factor: 1.087

3.  Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis.

Authors:  Shoji Ichikawa; Anthony M Austin; Amie K Gray; Matthew R Allen; Michael J Econs
Journal:  Endocrinology       Date:  2011-10-18       Impact factor: 4.736

Review 4.  Endocrine functions of bone in mineral metabolism regulation.

Authors:  L Darryl Quarles
Journal:  J Clin Invest       Date:  2008-12-01       Impact factor: 14.808

5.  Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13.

Authors:  M J Econs; P T McEnery; F Lennon; M C Speer
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

6.  Effects of the acute subcutaneous administration of synthetic salmon calcitonin in tumoral calcinosis.

Authors:  R Candrina; B Cerudelli; V Braga; A Salvi
Journal:  J Endocrinol Invest       Date:  1989-01       Impact factor: 4.256

7.  Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations.

Authors:  Shoji Ichikawa; Geneviève Baujat; Aksel Seyahi; Anastasia G Garoufali; Erik A Imel; Leah R Padgett; Anthony M Austin; Andrea H Sorenson; Zagorka Pejin; Vicken Topouchian; Pierre Quartier; Valerie Cormier-Daire; Michele Dechaux; Fotini Ch Malandrinou; Panagiotis N Singhellakis; Martine Le Merrer; Michael J Econs
Journal:  Am J Med Genet A       Date:  2010-04       Impact factor: 2.802

8.  Case report 500: Tumoral calcinosis in area of left hip.

Authors:  M Zawin; L D Katz; J P Lawson
Journal:  Skeletal Radiol       Date:  1988       Impact factor: 2.199

Review 9.  Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis.

Authors:  Aline Martin; L Darryl Quarles
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 10.  The structural biology of the FGF19 subfamily.

Authors:  Andrew Beenken; Moosa Mohammadi
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.